炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 10月23日消息，天臣医疗发布三季度报告。 责任编辑：小浪快报 公告显示，公司前三季度营业收入243,831,328.07元，同比增加20.66%，归属上市公司股东的净利润 71,945,750.36元，同比增加68.29%。 公告显示，十大流通股东中，马敬娥、何汝豪、林纯青为新进流通股东。 ...

天臣国际医疗科技股份有限公司2025 年第三季度报告 证券代码：688013 证券简称：天臣医疗 天臣国际医疗科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 87,663,076.62 | 26.40 | 243, ...

格隆汇10月23日丨天臣医疗(688013.SH)公布，公司前三季度实现营业收入2.44亿元，同比增长 20.66%；归属于上市公司股东的净利润7194.58万元，同比增长68.29%；归属于上市公司股东的扣除非 经常性损益的净利润6620.23万元，同比增长71.85%；基本每股收益0.90元。 ...

Core Insights - Tianchen Medical (688013) reported a significant increase in revenue and net profit for Q3 2025, with revenue reaching 87.66 million yuan, a year-on-year growth of 26.4% [1] - The company's net profit for Q3 was 23.73 million yuan, reflecting a substantial year-on-year increase of 70.74% [1] - For the first three quarters of 2025, Tianchen Medical achieved a total revenue of 244 million yuan, marking a year-on-year growth of 20.66% [1] - The net profit for the first three quarters was 71.95 million yuan, which is a year-on-year increase of 68.29% [1] - The basic earnings per share for the company stood at 0.9 yuan [1]

天臣医疗公告，第三季度营收为8766.31万元，同比增长26.40%；净利润为2373.42万元，同比增长 70.74%。前三季度营收为2.44亿元，同比增长20.66%；净利润为7194.58万元，同比增长68.29%。 ...

截至2025年10月10日收盘，天臣医疗(688013)报收于59.46元，下跌2.99%，换手率1.27%，成交量1.03万 手，成交额6187.05万元。 当日关注点 交易信息汇总资金流向 天臣国际医疗科技股份有限公司于2023年12月27日启动股份回购，原定实施期限至2024年12月26日，后 经调整延长至2025年12月26日。回购资金总额由最初1,800万元至3,600万元逐步上调至4,600万元至8,000 万元，资金来源包括公司自有资金及不超过3,465万元的中信银行专项贷款。回购股份拟用于员工持股 计划或股权激励。截至2025年9月30日，公司累计回购股份2,505,324股，占总股本的3.09%，已支付金 额约4,249.89万元，回购价格区间为11.87元/股至21.00元/股。2025年9月未进行回购交易。相关回购行 为符合法规及方案规定。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：10月10日主力资金净流入699.71万元，占总成交额11.31%。 来自公司公告汇总：天臣医疗股份回购累 ...

截至2025年10月10日收盘，天臣医疗（688013）报收于59.46元，较上周的60.36元下跌1.49%。本周， 天臣医疗10月9日盘中最高价报62.85元。10月10日盘中最低价报59.05元。天臣医疗当前最新总市值 48.26亿元，在医疗器械板块市值排名74/126，在两市A股市值排名3379/5158。 公司公告汇总 天臣医疗关于股份回购进展公告：公司于2023年12月27日启动股份回购，原定实施期限至2024年12月26 日，后延长至2025年12月26日。回购资金总额上调至4,600万元至8,000万元，资金来源包括自有资金及 不超过3,465万元的中信银行专项贷款，拟用于员工持股计划或股权激励。截至2025年9月30日，累计回 购股份2,505,324股，占总股本的3.09%，已支付金额约4,249.89万元，回购价格区间为11.87元/股至21.00 元/股。2025年9月未进行回购交易。相关回购行为符合法规及方案规定。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本周关注点 公司公告汇总：截至2025年9月 ...

Core Insights - Tianchen Medical (688013) reported a net financing purchase of 3.14 million yuan on October 9, 2025, with a financing balance of 204 million yuan, indicating a positive trend in investor interest [1][2][3] Financing Activity Summary - On October 9, 2025, the financing buy-in was 15.07 million yuan, while financing repayment was 11.93 million yuan, resulting in a net financing purchase of 3.14 million yuan [1] - The financing balance increased to 204 million yuan, with a 1.56% rise compared to the previous day [3] - Over the past three trading days, the cumulative net financing purchase reached 8.15 million yuan, and in the last 20 trading days, there were 13 days with net financing purchases [1] Financing Balance Trends - The financing balance on October 9, 2025, was 204 million yuan, which is 4.10% of the circulating market value [2] - The financing balance has shown a consistent upward trend, with previous balances recorded at 201 million yuan on September 30 and 197 million yuan on September 29 [2][3] - The financing balance has fluctuated, with a notable increase of 4.22% on September 26, 2025, before a decrease of 2.04% on September 25 [3]

Core Viewpoint - The company, Tianchen International Medical Technology Co., Ltd., has adjusted the upper limit of its share repurchase price following the implementation of its 2025 semi-annual equity distribution, reducing it from RMB 28.53 per share to RMB 28.03 per share, effective from October 16, 2025 [2][10]. Summary by Sections Share Repurchase Overview - On December 27, 2023, the company approved a share repurchase plan with a total fund of no less than RMB 18 million and no more than RMB 36 million, with a maximum repurchase price of RMB 30.00 per share, valid for 12 months [3][15]. - On July 9, 2024, the company increased the repurchase fund to a range of RMB 36 million to RMB 72 million, reflecting confidence in its future development [4][16]. - On December 25, 2024, the repurchase fund was further adjusted to between RMB 46 million and RMB 80 million, extending the repurchase period to December 26, 2025 [6][17]. Adjustment of Repurchase Price Limit - Following the 2025 semi-annual equity distribution, the repurchase price limit was adjusted from RMB 30.00 to RMB 29.51 per share [5]. - After the special dividend distribution in January 2025, the price limit was further adjusted to RMB 28.53 per share [8]. - The final adjustment post the 2025 semi-annual equity distribution set the price limit at RMB 28.03 per share, calculated based on the cash dividend of approximately RMB 0.4970 per share [10][11]. Repurchase Progress - As of September 30, 2025, the company had repurchased a total of 2,505,324 shares, representing 3.09% of its total share capital, with a total expenditure of approximately RMB 42.5 million [19].

Core Points - Tianchen Medical announced an adjustment to the maximum repurchase price of its shares following the implementation of the 2025 semi-annual equity distribution, lowering it from RMB 28.53 per share to RMB 28.03 per share [2] Summary by Category - **Company Announcement** - The company will adjust the maximum repurchase price for its shares to RMB 28.03 per share, effective from October 16, 2025, which is the ex-dividend date for the 2025 semi-annual equity distribution [2]